[1] Sun X,Hu F,Hou Z,et al.SIX4 activates Akt and promoles tumor angiogenesis.Exp Cell Res,2019,383(1):111495. [2] Sun X,Ma J,Chen Q,et al.SIX4 promotes metastasis through STAT3 activation in breast cancer. Am J Cancer Res,2020,10(1):224-236. [3] Corso G,Figueiredo J,De Angelis SP,et al.E-cadherin deregulation in breast cancer.J Cell Mol Med,2020,24(11):5930-5936. [4] 薛栋,舒孟良,张建,等.肝细胞癌组织中TRIM59、Akt及N-cadherin表达及其临床意义.中国老年学杂志,2020,40(22):4740-4743. [5] Makol A,Kaur H,Sharma S,et al.Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line. Clin Mol Hepatol,2020,26(1):45-53. [6] Peng Z, Fan W, Zhu B, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: A phase III, randomized clinical trial (LAUNCH). J Clin Oncol, 2023,41(1):117-127. [7] Casadei-Gardini A, Rimini M, Tada T, et al. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. Eur J Cancer, 2023,180:9-20. [8] Chiang CL, Chiu KWH, Chan KSK, et al. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. Lancet Gastroenterol Hepatol, 2023, 8(2):169-178. [9] Deng S, Solinas A, Calvisi DF. Cabozantinib for HCC treatment, from clinical back to experimental models. Front Oncol, 2021,11:756672. |